To the Editor： Letrozole, a third-generation aromatase inhibitor （AlL is a relatively newer class of endocrine agents used in hormone-receptor-positive breast cancer Vascular thrombotic events, such as acute myocard...To the Editor： Letrozole, a third-generation aromatase inhibitor （AlL is a relatively newer class of endocrine agents used in hormone-receptor-positive breast cancer Vascular thrombotic events, such as acute myocardial infarction and acute cerebral infarction, in patients with breast cancer after initiation of letrozole therapy have been documented in the literature However, the impact of this adjuvant endocrine therapy on increasing tile risk of developing vascular tbrombotic events has been a controversial issue. Here, we report a rare case of a woman with breast cancer developing unilateral internal carotid artery （ICA） occlusion alier letrozole treatment.展开更多
文摘To the Editor： Letrozole, a third-generation aromatase inhibitor （AlL is a relatively newer class of endocrine agents used in hormone-receptor-positive breast cancer Vascular thrombotic events, such as acute myocardial infarction and acute cerebral infarction, in patients with breast cancer after initiation of letrozole therapy have been documented in the literature However, the impact of this adjuvant endocrine therapy on increasing tile risk of developing vascular tbrombotic events has been a controversial issue. Here, we report a rare case of a woman with breast cancer developing unilateral internal carotid artery （ICA） occlusion alier letrozole treatment.
